Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

D Huang, Y Ding, M Zhou, BI Rini, D Petillo, CN Qian… - Cancer research, 2010 - AACR
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …
被引用次数：472 相关文章

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

D Huang, Y Ding, M Zhou, BI Rini… - Cancer …, 2010 - pubmed.ncbi.nlm.nih.gov
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

D Huang, Y Ding, M Zhou, BI Rini… - Cancer …, 2010 - utsouthwestern.elsevierpure.com
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …
[HTML] europepmc.org

[HTML][HTML] Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

D Huang, Y Ding, M Zhou, BI Rini, D Petillo… - Cancer …, 2010 - europepmc.org
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

D Huang, Y Ding, M Zhou, BI Rini, D Petillo, CN Qian… - Cancer …, 2010 - cir.nii.ac.jp
< jats: title> Abstract</jats: title>< jats: p> The broad spectrum kinase inhibitor sunitinib is a
first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of …

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

D Huang, Y Ding, M Zhou, BI Rini… - Cancer …, 2010 - mdanderson.elsevierpure.com
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

[引用][C] Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

DAN HUANG, YAN DING, M ZHOU… - Cancer research …, 2010 - pascal-francis.inist.fr
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell
Carcinoma CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
[HTML] nih.gov

[HTML][HTML] Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

D Huang, Y Ding, M Zhou, BI Rini, D Petillo… - Cancer …, 2010 - ncbi.nlm.nih.gov
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

D Huang, Y Ding, M Zhou, BI Rini, D Petillo… - Cancer …, 2010 - europepmc.org
The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

[引用][C] Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

DAN HUANG, YAN DING, M ZHOU… - Cancer …, 2010 - American Association for Cancer …